|
1
|
Speight PM and Barrett AW: Salivary gland
tumors. Oral Dis. 8:229–240. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bell D and Hanna EY: Salivary gland
cancers: biology and molecular targets for therapy. Curr Oncol Rep.
14:166–174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hunt JL: An update on molecular
diagnostics of squamous and salivary gland tumors of the head and
neck. Arch Pathol Lab Med. 135:602–609. 2011.PubMed/NCBI
|
|
4
|
Laurie SA and Licitra L: Systemic therapy
in the palliative management of advanced salivary gland cancers. J
Clin Oncol. 24:2673–2678. 2006. View Article : Google Scholar
|
|
5
|
Guzzo M, Locati LD, Prott FJ, Gatta G,
McGurk M and Licitra L: Major and minor salivary gland tumors. Crit
Rev Oncol Hematol. 74:134–148. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bensadoun RJ, Blanc-Vincent MP, Chauvel P,
Dassonville O, Gory-Delabaere G and Demard F: Malignant tumours of
the salivary glands. Br J Cancer. 84:42–48. 2001. View Article : Google Scholar
|
|
7
|
Yeow WS, Ziauddin MF, Maxhimer JB, et al:
Potentiation of the anticancer effect of valproic acid, an
antiepileptic agent with histone deacetylase inhibitory activity,
by the kinase inhibitor Staurosporine or its clinically relevant
analogue UCN-01. Br J Cancer. 94:1436–1445. 2006. View Article : Google Scholar
|
|
8
|
Shabbeer S, Kortenhorst MS, Kachhap S,
Galloway N, Rodriguez R and Carducci MA: Multiple molecular
pathways explain the anti-proliferative effect of valproic acid on
prostate cancer cells in vitro and in vivo. Prostate. 67:1099–1110.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosato RR, Almenara JA, Dai Y and Grant S:
Simultaneous activation of the intrinsic and extrinsic pathways by
histone deacetylase (HDAC) inhibitors and tumor necrosis factor
related apoptosis-inducing ligand (TRAIL) synergistically induces
mitochondrial damage and apoptosis in human leukemia cells. Mol
Cancer Ther. 2:1273–1284. 2004.
|
|
10
|
Wolffe AP: Transcription: in tune with the
histones. Cell. 77:13–16. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosato RR, Almenara JA, Yu C and Grant S:
Evidence of a functional role for p21WAF1/CIP1
down-regulation in synergistic antileukemic interactions between
the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Mol Pharmacol. 65:571–581. 2004.PubMed/NCBI
|
|
12
|
Bug G, Ritter M, Wassmann B, et al:
Clinical trial of valproic acid and all-trans retinoic acid
in patients with poor-risk acute myeloid leukemia. Cancer.
104:2717–2725. 2005.PubMed/NCBI
|
|
13
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schrump DS and Nguyen DM: Targeting the
epigenome for the treatment of thoracic malignancies. Thorac Surg
Clin. 16:367–377. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruefli AA, Ausserlechner MJ, Bernhard D,
et al: The histone deacetylase inhibitor and chemotherapeutic agent
suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway
characterized by cleavage of Bid and production of reactive oxygen
species. Proc Natl Acad Sci USA. 98:10833–10838. 2001. View Article : Google Scholar
|
|
16
|
Saunders N, Dicker A, Popa C, Jones S and
Dahler A: Histone deacetylase inhibitors as potential anti-skin
cancer agents. Cancer Res. 59:399–404. 1999.PubMed/NCBI
|
|
17
|
De Ruijter AJ, van Gennip AH, Caron HN,
Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs):
characterization of the classical HDAC family. Biochem J.
370:737–749. 2002.PubMed/NCBI
|
|
18
|
Grozinger CM, Hassig CA and Schreiber SL:
Three proteins define a class of human histone deacetylases related
to yeast Hda1p. Proc Natl Acad Sci USA. 96:4868–4873. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blaheta RA and Cinatl J: Anti-tumor
mechanisms of valproate: a novel role for an old drug. Med Res Rev.
22:492–511. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yanagawa T, Hayash Y, Nagamine S, Yoshida
H, Yura Y and Sato M: Generation of ceils with phenotypes of both
intercalated duct-type and myoepithelial cells in human parotid
gland adenocarcinoma clonal cells grown in a thymic nude mice.
Virchows Arch. 51:187–195. 1986. View Article : Google Scholar
|
|
21
|
Shirasuna K, Sato M and Miyazaki T:
Aneoplastic epithelial duct cell line established from an
irradiated human salivary gland. Cancer. 48:745–752. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guan XF, Qiu WL, He RG and Zhou XJ:
Selection of adenoid cystic carcinoma cell clone highly metastatic
to the lung: an experimental study. Int J Oral Maxillofac Surg.
26:116–119. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uchida D, Begum NM, Aimofti A, Kawamata H,
Yoshida H and Sato M: Frequent downregulation of 14-3-3 σ protein
and hypermethylation of 14-3-3 σ gene in salivary gland
adenoid cystic carcinoma. Br J Cancer. 91:1131–1138. 2004.
|
|
24
|
Uchida D, Onoue T, Begum NM, et al:
Vesnarinone downregulates CXCR4 expression via upregulation of
Kruppel-like factor 2 in oral cancer cells. Mol Cancer. 8:622009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wittenburg LA, Bisson L, Rose BJ, Korch C
and Thamm DH: The histone deacetylase inhibitor varproic acid
sensitizes human and canine osteosarcoma to doxorubicin. Cancer
Chemother Pharmacol. 67:83–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang H, Reed CP, Zhang JS, Shridhar V,
Wang L and Smith DI: Carboxypeptidase A3 (CPA3): a novel gene
highly induced by histone deacetylase inhibitors during
differentiation of prostate epithelial cancer cells. Cancer Res.
59:2981–2988. 1999.
|
|
27
|
Sambucetti LC, Fischer DD, Zabludoff S, et
al: Histone deacetylase inhibition selectively alters the activity
and expression of cell cycle proteins leading to specific chromatin
acetylation and antiproliferative effects. J Biol Chem.
274:34940–34947. 1999. View Article : Google Scholar
|
|
28
|
Siavoshian S, Blottiere HM, Cherbut C and
Galmiche JP: Butyrate stimulates cyclin D and p21 and inhibits
cyclin-dependent kinase2 expression in HT-29 colonic epithelial
cells. Biochem Biophys Res Commun. 232:169–172. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Erlich RB, Rickwood D, Coman WB, Saunders
NA and Guminski A: Valproic acid as a therapeutic agent for head
and neck squamous cell carcinomas. Cancer Chemother Pharmacol.
63:381–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gottlicher M, Minucci S, Zhu P, et al:
Valproic acid defines a novel class of HDAC inhibitors inducing
differentiation of transformed cells. EMBO J. 20:6969–6978. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen CL, Sung J, Cohen M, et al: Valproic
acid inhibits invasiveness in bladder cancer but not in prostate
cancer cells. J Pharmacol Exp Ther. 319:533–542. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Greenblatt MS, Bennett WP, Hollstein M and
Harris CC: Mutations in the p53 tumor suppressor gene: clues to
cancer etiology and molecular pathogenesis. Cancer Res.
54:4855–4878. 1994.PubMed/NCBI
|
|
33
|
Vaziri C, Stice L and Faller DV:
Butyrate-induced G1 arrest results from p21-independent disruption
of retinoblastoma protein-mediated signals. Cell Growth Differ.
9:465–474. 1998.PubMed/NCBI
|
|
34
|
Sidana A, Wang M, Shabbeer S, et al:
Mechanism of growth inhibition of prostate cancer xenografts by
valproic acid. J Biomed Biotechnol. 2012:1803632012. View Article : Google Scholar : PubMed/NCBI
|
